What is TLSI's health score?

TriSalus Life Sciences, Inc. (TLSI) has a TradeApes health score of 42 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is TLSI's estimated fair value?

Based on our 5-year discounted cash flow model, TriSalus Life Sciences, Inc.'s estimated fair value is $2.2 per share, representing a -33.3% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is TLSI undervalued or overvalued?

Our model currently rates TLSI as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for TLSI... Refresh in a moment for the full analysis.

TriSalus Life Sciences, Inc. (TLSI)

Healthcare Overvalued low weak

$3.3

Updated: 2026-06-05

TradeApes Score

Financial Strength

35 Weak

Operating Trend

73 Healthy

Relative Value

40 Weak

Capital Allocation

10 Stressed

Risk

35 Weak

Est. Fair Value $2.2

DCF Upside -33.3%

Sector Rank #538 of 6667

Key Findings

+ Strong revenue growth — sales up more than 20% year over year

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

3 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.